Interferon-alpha for chronic hepatitis C: reducing the uncertainties

Article Abstract:

Evidence is mounting that interferon-alpha may be both effective and affordable in the treatment of chronic hepatitis C. Three studies provide support for this optimistic outlook. A 1 to 7.6-year follow-up study on 80 patients who had a sustained response to therapy after 6 months found that the response was maintained in the majority of the patients. Another analysis indicates that 6 months of interferon-alpha therapy for mild chronic hepatitis C is beneficial and cost effective. The third supports the advantages and cost-effectiveness of 12 months of therapy compared to 6 months, and no treatment.

Editorial, Drug therapy

---

Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium

Article Abstract:

The authors discuss the current day situation of hepatitis B viral infection, the leading cause of liver cancer and cirrhosis in the world. Hepatitis B infection is especially widespread in southeast Asia, China, and Africa, where it there are areas in which the infection rate is nearly 10% of the population. About 1.25 million people in North America and Europe are infected. treatment was once limited to interferon-alfa, but advances have been made in the field of nucleoside analogues such as lamivudine, which is effective to one degree or another in almost every patient.

Hepatitis B, Lamivudine

---

Does interferon-alpha prevent recurrence of malignant tumors in patients with hepatitis C-related liver cancer?

Article Abstract:

Interferon-alpha may prevent the re-occurrence of liver cancer caused by hepatitis C in patients who had the initial tumor surgically removed. In a study of 30 patients, the cancer recurred in 5 of the 15 who took interferon-alpha and in 12 of the 15 who did not take interferon-alpha.

Prevention, Cancer, Liver cancer, Complications, Cancer recurrence

Similar abstracts:

• Abstracts: Interferon beta-1B for multiple sclerosis. Glatiramer acetate for relapsing multiple sclerosis. Interferon beta-1a for relapsing multiple sclerosis
• Abstracts: Caring for neonates. Taking the strain. Tuberculosis in homeless people
• Abstracts: Hard-arm vibration research. Finding the fatal fibre
• Abstracts: Prevalence of selected risk factors for chronic disease by education level in racial ethnic populations - United States, 1991-1992
• Abstracts: Visual impairment in a rural Appalachian community: prevalence and causes. Acute Onset of Decreased Vision and Hearing Traced to Hemodialysis Treatment With Aged Dialyzers

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.